SABCS 2025: Favorable Benefit–Risk Profile of Sacituzumab Govitecan in Previously Untreated Metastatic TNBC PD-L1–ineligible Metastatic Triple-Negative Breast Cancer

New ASCENT-03 data highlight sacituzumab govitecan as an effective first-line option with a manageable safety profile for patients with metastatic triple-negative breast cancer who are ineligible for PD-L1–targeted therapy.